RxDoctor Payments Data

Elizabeth Koontz

Nurse Practitioner · Charleston, SCNPI 1831341122

Payments from drug & device makers

$5,646in general payments, 2019–2025

Across 17 payments — averaging $332.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$5K
  • Neuropace, Inc.$525
  • Livanova USA, Inc.$150
  • Jazz Pharmaceuticals Inc.$138
  • AbbVie$106
  • UCB, Inc.$91
  • plus $75 from 2 others

What the payments were for

  • Consulting fees$3,52562%
  • Speaking & faculty fees$1,25022%
  • Food & beverage$87115%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,646 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$28,766
Medicare patients
184
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate553$763,612
EpidiolexCannabidiol (Cbd)90$425,692
BriviactBrivaracetam109$182,531
Lacosamide552$71,609
Rufinamide28$49,038
KeppraLevetiracetam23$47,539
NayzilamMidazolam41$45,735
LamictalLamotrigine26$41,128
VimpatLacosamide32$33,867
Levetiracetam604$30,942
Clobazam192$27,538
OnfiClobazam13$23,629
Nurtec OdtRimegepant Sulfate12$21,690
FycompaPerampanel18$21,472
Aimovig AutoinjectorErenumab-Aooe11$20,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$4,562$763,612553 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$91$262,133182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →